Osaka, Japan, June27, 2019, --- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ('Takeda') today announced new assignment of Directors. The details are as follows;

1.New assignment of Non-Audit and Supervisory Committee Directors effective June 27, 2019;

Name

Category

Role

Christophe Weber

Internal

Existing

Representative Director,
President & Chief Executive Officer

Masato Iwasaki

Internal

Existing

Director, President, Japan Pharma Business Unit

Andrew Plump

Internal

Existing

Director, President, Research & Development

Constantine Saroukos

Internal

New

Director, Chief Financial Officer

Masahiro Sakane

External

Existing

External Director, Chair of the Board Meeting

Olivier Bohuon

External

Existing

External Director

Jean-Luc Butel

External

New

External Director

Ian Clark

External

Existing

External Director

Yoshiaki Fujimori

External

Existing

External Director

Steven Gillis

External

Existing

External Director

Shiro Kuniya

External

New

External Director

Toshiyuki Shiga

External

Existing

External Director

2.New assignment of Audit and Supervisory Committee Directors effective June 27, 2019;

Name

Category

Role

Yasuhiko Yamanaka

Internal

-

Director, Audit & Supervisory Committee member

Koji Hatsukawa

External

-

External Director, Chairperson of Audit & Supervisory Committee

Emiko Higashi

External

New

External Director, Audit & Supervisory Committee member

Michel Orsinger

External

New

External Director, Audit & Supervisory Committee member

Yasuhiko Yamanaka and Koji Hatsukawa are within their 2-year tenure of Audit and Supervisory Committee Director, and were not subjects for reelection this year.

3.New assignment of Compensation committee and Nomination committee effective June 27, 2019;

- Compensation committee : Emiko Higashi (Chair), Olivier Bohuon, Ian Clark, Yoshiaki Fujimori
- Nomination committee : Masahiro Sakane (Chair), Jean-Luc Butel, Steven Gillis,
Toshiyuki Shiga, Michel Orsinger, Christophe Weber (Observer)

Media Contact:
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095

Attachments

  • Original document
  • Permalink

Disclaimer

Takeda Pharmaceutical Co. Ltd. published this content on 28 June 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 June 2019 05:40:03 UTC